COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #165
Source   PDF   Share   Tweet
See all 181 studies
Post Exposure Prophylaxis study (treated after exposure to the virus)
Dhibar et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224 (Peer Reviewed)
Post Exposure Prophylaxis with Hydroxych loroquine (HC Q) for the Prevention of COVID-19, a Myth or a Reality? The PEP-C Q Study
41% reduction in cases with HC Q PEP. Prospective open label trial with 132 HC Q patients and 185 control patients showing RR 0.59, p=0.03.
50% reduction in PCR+ cases, 44% reduction in symptomatic cases.
No serious adverse events. Relatively low dosage, the PEP group received HC Q 800mg on day one followed by 400mg once weekly for 3 weeks. NCT04408456
COVID-19 case, ↓41.0%, p=0.03
COVID-19 case, ↓50.0%, p=0.04, PCR+
symptomatic case, ↓43.9%, p=0.21
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.